Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 4 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.


Player Avatar FutureMonkey (81.64) Submitted: 2/11/2008 9:29:24 AM : Outperform Start Price: $18.25 VRTX Score: +33.94

This is an all or none play on their phase III Hepatitis protease inhibitor therapy - Telaprevir. If this drug comes close to expectations VRTX at below $20 is a bargain. Yes, this company has other promising drugs in the pipeline; however the value of those products is offset by the risk of competition and a fickle FDA. Therefore I focus almost exclusively on the flagship Telaprevir for success or failure of VRTX's market cap.

Featured Broker Partners